Data updated: May 26, 2026
Vaxneuvance (pneumococcal 15-valent conjugate vaccine)
Approved 2021-07-15
1
Indication
--
Phase 3 Trials
4
Years on Market
Details
- Status
- Prescription
- First Approved
- 2021-07-15
- Patent Cliff
- 2033
- Revenue
- $161M (Q4-2024)
- Routes
- Intramuscular
- Dosage Forms
- Injection
Vaxneuvance Approval History
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2021 to 2021
Jul 2021 ORIGINAL
Update · CBER biologic (Purple Book)
What Vaxneuvance Treats
1 FDA approvalsOriginally approved for its first indication in 2021 .
- Other (1)
Other
(1 approval)- • Approved indication (Jul 2021)
📋
Clinical Trial Registry
4 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06855160 | 223105 2024-518840-18-00 | Ph 3 | recruiting | A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age |
| NCT06806137 | 214002 2024-516635-27-00 | Ph 3 | recruiting | A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age |
| NCT06740630 | 213998 2024-515869-33-00 | Ph 3 | recruiting | A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age |
| NCT06693895 | 213997 2024-515868-31-00 | Ph 3 | recruiting | A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
Vaxneuvance FDA Label Details
Pro Intelligence Preview
Deep insights for Vaxneuvance
Revenue Insights
- • Q4-2024: $161M
- • Historical trend analysis
Patent Timeline
- • Cliff: 2033
- • Generic/biosimilar risk
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Unlock Full Intelligence
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.